中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-09-07
UBT251 INJECTION COMPLETED FIRST PARTICIPANT DOSING IN PHASE III CLINICAL STUDY FOR OVERWEIGHT OR OBESITY IN CHINA
Learn More
2026-09-07
Significant Progress in Innovative Drug R&D and Continued Globalization Efforts Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million
Learn More
2026-08-12
FDA APPROVAL OF IND FOR THE GROUP’S PRODUCT UBT48128 TABLETS
Learn More
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
All News
Select Year
2026
2025
2024
TUL’s Amoxil Ranks Among the “2024–2025 Best-Selling Products in China’s Pharmaceutical Retail Market” and Wins the “2024–2025 CPHCF Award”
2025-03-17
Zhuhai United Laboratories Co., Ltd. Passes Brazilian Official GMP Inspection
2025-03-17
TUL Debuts at VIV Asia 2025, Embarking on a New Global Journey
2025-03-15
TUL’s Ceftriaxone Sodium for Injection Passes Generic Drug Consistency Evaluation in Quality and Efficacy
2025-03-07
TUL Participates in Beijing International Pet Products Exhibition, Energizing the Pet Health Industry
2025-03-04
The “100 Enterprises, 100 Hospitals – Guangdong Medical Tour” Visits TUL to Jointly Build A New Future for Pharmaceutical Development
2025-02-28
Enrofloxacin Granules Receive Class IV New Veterinary Drug Certificate; Streptomycin Sulfate for Injection Gains Approval for Registration Change
2025-02-07
The Marketing Application of TUL’s Semaglutide Injection Accepted by the National Medical Products Administration
2025-01-24
TUL’s UBT251 Injection Receives FDA IND Approval for Chronic Kidney Disease Indication
2025-01-22
Prev
1
...
9
10
11
12
13
...
17
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
